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Abstract
Background: Hyperthermia therapy (HT) has shown to be an effective adjuvant to radiation, chemotherapy, and
immunotherapy. In order to be safe and effective, delivery of HT requires maintenance of target tissue temperature
within a narrow range (40–44 °C) for 30–60 min, which necessitates conformal heat delivery and accurate temperature
monitoring. The goal of this project was to develop an MR thermometry-guided hyperthermia delivery platform based
upon the ExAblate prostate array that would achieve uniform stable heating over large volumes within the prostate,
while allowing the user to precisely control the power deposition patterns and shape of the region of treatment (ROT).
Methods: The HT platform incorporates an accelerated multi-slice real time MR thermometry pulse sequence and
reconstruction pipeline. Temperature uniformity over a large contiguous area was achieved by multi-point temperature
sampling with multi-focal feedback power control. The hyperthermia delivery system was based on an InSightec
ExAblate 2100 prostate focused ultrasound ablation system, and HeartVista’s RTHawk real-time MRI system integrated
with a 3 T MRI scanner. The integrated system was evaluated in experiments with a tissue-mimicking phantom for
prolonged exposures with a target temperature increase of 7 °C from baseline.
Results: Five various shapes of the region of treatment, defined on a 5 × 5 grid (35 × 35 mm, 11–25 focal spots per
shape), were implemented to evaluate the performance of the system. MR temperature images, acquired after steady
state was reached, showed different patterns of heating that closely matched the prescribed regions. Temperature
uncertainty of the thermometry acquisition was 0.5 °C. The time to reach the target temperature (2:58–7:44 min)
depended on the chosen ROT shape and on the distance from transducer to focal plane. Pre-cooling with circulating
water helped to reduce near-field heating.
Conclusions: We have implemented a real-time MR thermometry-guided system for hyperthermia delivery within
user-defined regions with the ExAblate prostate array and evaluated it in phantom experiments for different shapes
and focal depths. Our results demonstrate the feasibility of using a commercially available endorectal FUS transducer to
perform spatially-conformal hyperthermia therapy and could lead to a new set of exciting applications for these
devices.
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Background
Hyperthermia therapy (HT) involves raising the
temperature of the target tissue to 40–44 °C for
30–60 min. It has shown promise as an adjuvant to radi-
ation, chemotherapy, and immunotherapy for the treat-
ment of cancer [1–3]. Recent reviews clearly indicate that
HT in conjunction with radiation and/or chemotherapy
can significantly improve local control and overall survival
for deep and superficial tumors [4, 5]. In pelvic cancers,
randomized clinical trials determined that HTadded to ra-
diation therapy can improve treatment outcomes for ad-
vanced and recurrent cervical cancer [6–10], prostate
cancer [11, 12], and persistent pelvic tumors [13]. HT aug-
mented chemotherapy has been proven to increase overall
survival in patients with soft tissue sarcoma [14–16].
Clinical studies have demonstrated feasibility and efficacy
of prostate hyperthermia with endorectal ultrasound appli-
cators in combination with radiation therapy [11, 17, 18].
In all these applications of hyperthermia therapy, ac-
curate thermal dosimetry and heating conformability are
essential for good response. In order to be safe and ef-
fective, HT requires maintenance of target tissue
temperature within a narrow range (40–44 °C), avoid-
ance of excessive temperatures, which are associated
with complications. Thermal dose, measured in CEM43°
C (a cumulative equivalent number of minutes at 43 °C)
has been used to quantify the amount of thermal expos-
ure during the treatment. For HT, depending upon the
heating regimen, a minimum delivered thermal dose
threshold of approximately 5–10 CEM43°C T90 (90% of
measured points exceeding this value) must be reached
[10, 19–21]. This necessitates methods for precise heat
delivery and accurate temperature monitoring.
MR imaging techniques, such as proton resonance fre-
quency shift imaging (PRFS) [22], are capable of
non-invasive temperature monitoring of hyperthermia
and thermal ablation procedures. MR thermometry is
commonly used to monitor high temperature ablation of
deep tissues with techniques, such as MR-guided fo-
cused ultrasound (MRgFUS) therapy, where focused
high intensity ultrasonic energy is delivered from an
extracorporeal transducer in repeated short sonications.
MR thermometry has been successfully utilized for mon-
itoring [23, 24] and control [25] of HT treatments with
radiofrequency applicators for heating deep tumors
within the pelvis and trunk. MR-guided ultrasound
hyperthermia (MRgHT), which uses similar technologies
to MRgFUS for prolonged heating at sub-lethal tempera-
tures, has been demonstrated in research studies, but is
yet to be available clinically. A multi-element ultrasound
array for hyperthermia delivery to the prostate has been
investigated for control of hyperthermia and drug deliv-
ery under MRI guidance [26, 27]. Staruch et al. devel-
oped a focused ultrasound system that performed HT
delivery with mechanical scanning of a custom-made
ultrasound transducer and closed-loop temperature
feedback control [28].
There is interest in utilizing commercially available
MRgFUS systems, designed and approved for thermal ab-
lation, for delivery of prolonged moderate heating by
modifying their control systems. Using the Philips Sonal-
leve platform with sparse phased array in-table transduc-
ers, Partanen and colleagues implemented a number of
approaches for MR-guided HT, such as single focus, sim-
ultaneous multi-focus and rapid sweeping trajectories
[29], along with separate heat-up and heat maintaining
subtrajectories with MR thermometry feedback [30]. The
MRgHT system developed by Tillander, et al. heated
smaller cells (18–58 mm) by electronic steering of the
beam in concentric circles and mechanical transducer
steering to cover larger areas [31]. We have previously
demonstrated the use of a commercial focused ultrasound
(FUS) system to achieve protracted hyperthermia delivery
HT [32] using a single region of interest (ROI) and
proportional-integral feedback power control. These in
vivo studies were useful to establish the feasibility of gen-
erating enough sustained power output with the ExAblate
prostate array (InSightec, Haifa, Israel) to deliver hyper-
thermia. It became clear, however, that in order to offer
more adjustable and precise delivery of uniform HT to or-
gans such as prostate, there is a need for heating with
multi-point thermometry feedback and spatial beam con-
trol that could be sustained over long durations.
The objectives of this project were to develop and
evaluate an integrated software platform to drive a com-
mercial endorectal prostate ablation array for MR
thermometry-guided HT delivery. A technique for con-
formal power deposition, based upon multi-point
temperature feedback power control and up to 25
pre-set focal patterns, has been devised for improved
spatial control of energy delivery within a region of
treatment (ROT). This multi-focal approach required
MR thermometry imaging with high frame rate and low
processing delay. Therefore, an accelerated multi-slice
real-time MR thermometry pulse sequence and recon-
struction pipeline specific for guidance, monitoring, and
control of the prostate array were incorporated. This in-
tegrated system was designed to achieve uniform stable
heating over large volumes, while allowing the user to
precisely control power deposition patterns and the
shape of the region of treatment (ROT).
Methods
System overview
The hyperthermia delivery system was based on an ExA-
blate 2100 prostate focused ultrasound system, and an
RTHawk real-time MRI system (HeartVista, Inc., Menlo
Park, CA) integrated with a 3 T MRI scanner (GE
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Healthcare, Waukesha, WI). The ExAblate endorectal
array (23 × 40 mm size) operated at a center frequency
of 2.3 MHz with approximately 1000 independently con-
trolled elements [33, 34]. The system is capable of elec-
tronic focusing and rapid switching between up to 32
preset focal patterns. Acoustic coupling and cooling
were performed with chilled water (12–14 °C), circulat-
ing inside a balloon and enveloping the transducer array.
Imaging was performed with the body coil. As the ExA-
blate system was designed for tumor ablation with short
focused sonications, it required significant operational
modifications to enable prolonged controlled heating of
large areas, necessary for HT delivery. For this project,
in order to control the prostate array, an integrated soft-
ware was developed that included a feedback control
loop, an accelerated MR thermometry acquisition and
reconstruction application, a beam controller module,
and an interface to the manufacturer’s hardware control
system (Fig. 1).
Accelerated real-time MR thermometry
An accelerated real-time MRgHT application (Fig. 2)
was developed on the RTHawk platform. It allowed con-
tinuous acquisition and reconstruction of temperature
maps with minimal latency using a spoiled gradient echo
(SPGR) pulse sequence, a real-time proton resonance
frequency shift (PRFS) thermometry reconstruction
pipeline, and a custom interface for data visualization
and prescription.
The pulse sequence implemented a shared k-space with
keyhole acceleration technique [35], where the central part
of k-space was fully sampled and acquired for every im-
aging frame. Peripheral lines of k-space were split into al-
ternating sets that were updated less often (Fig. 3). Raw
data was transmitted over a local area network to the
RTHawk workstation and reconstructed in real-time. The
system supported interleaved acquisition of multi-planar
MR thermometry data with variable frame rates.
Beam controller
Temperature values within each MR thermometry frame
were sampled within the cells of a 5 × 5 grid that was
placed over the region of treatment in the control im-
aging plane perpendicular to the US beam direction.
The FUS system was set up with a library of 25
pre-generated single focus patterns that matched the
cells of the grid, covering in the case of our experiments
a 35 × 35 mm area. The size of this area and localization
of the focal points would be configured based on patient
anatomy before each treatment. To control the shape of
the region, individual cells of the grid can be turned on
and off in the application user interface. This allows for
the heated area to conform to the shape of the tumor in
the HT treatment. In this study, five distinct shapes of
the region of treatment within this grid were imple-
mented to evaluate the performance of the system:
square, elliptical, diagonal, triangular, and rhombic.
The controller module determined the next focal point
and power level, which were communicated over the net-
work to the FUS system via a Control Proxy Server appli-
cation (Fig. 1). To achieve uniform heating of the desired
area the beam controller directed the beam towards the
cell with the lowest temperature within the grid. Based on
the measured mean temperature (T) within this cell, the
controller modulated the power output of the transducer.
To reach the target temperature in the shortest amount of
time, the output was set to maximum power selected for
the treatment (P = Pmax) during the heat up stage
(T < Ttarget - 0.5 °C). Approaching the target temperature
(Ttarget - 0.5 °C < T < Ttarget) a proportional controller was
used (P = Pmax * (Ttarget - T) / 0.5°). At or above the target
temperature (T≥Ttarget), the power output was set to zero
(P = 0). Also, as a safety precaution, the power output was
set to zero if no thermometry images in the control plane
are received in 3 s.
Experimental setup
The integrated hyperthermia control system was evalu-
ated in experiments with a tissue-mimicking phantom
(InSightec) with thermal and acoustic properties of
non-perfused tissue (heat conductivity ~ 0.38 W/(m*°C),
TissueBeam Controller
Real-Time MR Thermometry
MR Scanner
RTHawk Research Platform
Control Proxy Server
Network
Ultrasound Control Software
Prostate Transducer
Network
Fig. 1 Control flow diagram of the MR thermometry-based hyperthermia
delivery system. The RTHawk research platform acquires and reconstructs
the real-time MRI data. The real-time MR thermometry application
generates temperature maps. The beam controller samples temperature
values within a grid of ROIs and controls the focus and power output of
the ultrasound beam, ensuring constant and uniform heating within the
region of treatment. The control proxy server relays commands from the
beam controller to the manufacturer’s ultrasound control software
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density = 1.05 g/cc, heat capacity 4.2 J/(g*K)). Prolonged
exposures with a target temperature increase of 7 °C from
baseline were prescribed. The phantom was placed in a
container with a bottom mylar membrane, submerged in
water at ambient temperature of approximately 20 °C and
positioned over the ultrasound transducer. Several
MRgHT experiments with different ROT shapes and soni-
cations parameters were performed as described in
Table 1.
The purpose of experiment 1 was to evaluate the ability
to achieve heating patterns that matched the prescribed
ROT shapes in the coronal plane. The MR thermometry
imaging slice used for beam control was placed at the level
of the ROT orthogonal to the beam axis. Images
(256 × 128 matrix, TE = 13 ms, TR = 29 ms, FOV = 24 cm,
readout bandwidth = 12.5 kHz, slice thickness = 3 mm)
were acquired with 32 lines of central k-space at every
frame and an interleave factor of 2 for peripheral k-space,
resulting in a 1.6× acceleration over the fully-sampled ac-
quisition. Temperature was sampled within a 35 × 35 mm
grid ROI (5 × 5 cells, 7 × 7 mm each).
In experiments 2 and 3, the focal plane was placed at two
different levels (60 and 35 mm) and near-field and far-field
heating during the treatment was monitored in an axial im-
aging slice, positioned along the beam axis. The control
and monitoring frames were interleaved with one monitor-
ing frame acquired after eight control frames (every 22 s).
Experiment 4 investigated the effect of pre-cooling the
near-field area before treatment. Chilled water (12 °C)
Fig. 2 User interface of the real-time MR thermometry application, showing a temperature map overlaid on top of the coronal magnitude image
(top-left), sagittal and axial navigator images with the phantom in a water container on top of the focused ultrasound transducer (top-right, bottom-left),
and control panel (bottom-right)
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Fig. 3 Diagram of the shared k-space with keyhole accelerated
readout for an interleaving factor of 2. Odd lines in the periphery of
the k-space (red) are updated on odd frames, even lines on even
frames (blue), and central lines on every frame (purple), achieving
1.6× acceleration
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was circulated in the balloon surrounding the transducer
for 28 min before hyperthermia started. MR thermometry
measurements were verified with a fiber-optic probe, em-
bedded in the phantom outside the beam path.
Results
Multiple heating trials were performed to evaluate sys-
tem performance, as summarized in Table 1. The table
shows the time it took to reach steady state and the dur-
ation of steady state heating in each experiment. MR
temperature images from experiment 1 and 3, acquired
after steady state was reached, showed different patterns
of heating that closely matched the prescribed regions
(Fig. 4). Temperature uncertainty of the thermometry
acquisition was 0.5 °C. Figure 5 shows temperature plots
for the cells of ROTs in experiments 1 and 3. The aver-
age temperature within the ROT increased until it lev-
eled off near the target temperature. There were brief
interruptions in power output of the transducer due to
software limits on continuous sonication, as can be seen
in Fig. 5 (top) after the 4-min mark.
The time to reach the target temperature depended on
the chosen ROT shape and on the distance from the
transducer to the focal plane, as seen in Table 1 and Fig. 5.
For the square heating pattern in experiment 1, the whole
region of treatment reached the target temperature after
around 7 min. The elliptical ROT, covering a smaller area,
reached steady state in half that time. The rhombic ROT
with focal plane at 60 mm from the transducer
(experiment 2) took around 6 min to reach steady state.
Reducing this distance to 35 mm (experiment 3) reduced
the time to around 3 min.
After the ROT reached the target temperature, stable
heating was maintained for 4–9 min (Table 1). Figure 5
shows the temperature of the cells of the ROT in experi-
ment 1 (square pattern, mean: 7.3 °C, range: 6.2–8.8 °C)
and in experiment 3 (rhombic pattern, mean: 7.4 °C,
range: 5.7–9.1 °C). The cells at the periphery of the ROT
experienced higher fluctuations in temperature due to
heat dissipation into the surrounding area, whereas the
inner cells had less variation. Data from experiment
3 showed higher fluctuation of mean temperature than
that of experiment 1. This was caused by increased rate
of heating due to the focal plane being closer to the
transducer and by brief sonication pauses while the sys-
tem was acquiring monitoring thermometry images
(every 22 s). There were image artifacts in one coronal
thermometry frame following each axial monitoring
frame due to spin steady state effects. These frames were
excluded from analysis.
In order to reach the target temperature within a large
region in a reasonable amount of time, the transducer
initially operated at high power (20-27 W) that was
Table 1 Summary of experiments performed with the system
Experiment ROT shapes Near field
monitoring
Depth Acoustic
power
Pre-cooling
time (min)
Time to target
temperature (min)
Time at steady
state (min)
1 square No 60 mm 26.8 W – 7:44 5:04
elliptical 3:24 4:19
diagonal 6:59 5:26
triangular 6:39 9:34
2 rhombic Yes 60 mm 20 W – 6:11 5:29
3 rhombic Yes 35 mm 20 W – 2:50 8:18
4 rhombic Yes 35 mm 20 W 28 2:58 8:13
 0
 6
 12°C
35 m
m
Fig. 4 Examples of prescribed regions of treatment (square, elliptical,
diagonal, triangular, and rhombic), and corresponding MR thermometry
images, acquired during the heating in experiments 1 and 3, showing
the flexibility to control the shape of the heated area. Peak temperatures
corresponded to recently active focal points
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reduced after approaching the target temperature. Fast
imaging was important to minimize the risk of overheat-
ing the tissue at the beam focus during the intervals be-
tween focus changes. The shared k-space with keyhole
acceleration technique allowed to improve the acquisi-
tion frame rate from 3.7 to 2.3 s update time per frame
and provided for a smoother heating curve.
Experiments 2 and 3 investigated pre-focal heating
when sonicating at two different depths with near-field
monitoring in the transverse plane. As expected, while it
was possible to achieve and control target temperature
increase at the depth of 60 mm from the transducer
(experiment 2), this depth was beyond the effective
focusing range of this phased array in soft tissue,
which resulted in excessive near-field heating of up to
+ 22 °C. In vivo, this would have caused tissue abla-
tion. In experiment 3 the target plane was set at
35 mm from the transducer. This decreased the
temperature elevation in the near-field to + 9 − + 12 °C
from baseline.
In experiment 4 (Fig. 6), pre-cooling with circulating
water has decreased the temperature near the bottom of
the phantom to − 13 °C from baseline, and it remained
at or below baseline for the duration of the heating. The
cooled area extended 16 mm from the bottom surface of
the phantom during the cooling stage and around 3 mm
during heating. The tissue in the beam path further from
the surface (3–25 mm) experienced heating of up to + 9
− + 10 °C from baseline. The temperature in the phan-
tom outside the beam path increased by around 1 °C
during heating due to thermal diffusion from the region
of treatment. The fiber-optic probe measurements
showed absolute temperature increase from 19.3 to
20.3 °C during the same period.
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Fig. 5 Plots of mean temperature values within cells of the ROT (each cell represented by a different color) and mean temperature of the whole
ROT (black) for experiment 1 (top, 60 mm focal depth, square pattern) and experiment 3 (bottom, 35 mm heating depth, rhombic pattern). Brief
power output interruption due to the limits on continuous sonication can be seen in the top figure after the 4 min mark and in the bottom figure
after the 2 min mark
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Discussion
There have been recent developments in MRgHT using
existing commercial ablation systems that underscore
the promise of this treatment modality. Previous ap-
proaches with the Sonalleve MR-HIFU system (Philips,
Profound Medical) utilized treatment cells composed of
concentric sub-trajectories [29, 31]. Our previous devel-
opment for an endorectal phased array transducer fea-
tured diverging or fixed beams with power modulation
[32]. This approach controlled the mean temperature of
the ROT, but it allowed little control of temperature dis-
tribution within the ROT. The approach described in
this paper enables conformal heating to precisely control
the shape of the temperature profile within a selected
area. Electronic steering of the beam based on real-time
MR thermometry data provided for uniform temperature
within the ROT defined on the control plane.
Multi-planar thermometry allowed to monitor near- and
far-field heating.
The HT system, described in this paper was designed
to provide precise conformal heating of a 2D ROT per-
pendicular to the beam direction. For precise 3D ROT
shaping, a 3D set of sampling locations with correspond-
ing focal positions could be used, with additional
temperature images obtained in a multi-slice or
multi-planar acquisition.
The time to reach the target temperature depended on
the chosen ROT shape, and on the distance from the
transducer to the focal plane. Even for the largest ROT
area (35 × 35 mm square) and large distance (60 mm),
the target temperature was reached in about 7 min,
which would be sufficient for hyperthermia treatments
without requiring longer procedure times. In our experi-
ments, stable heating was maintained for up to 9 min
due to time constraints. There were no technical limits
that would prevent the system from maintaining HT for
longer periods of time (30–60 min).
The power control scheme implemented in this paper
used several levels: maximum power selected for the
treatment during heat-up, a variable power setting near
the target temperature, to zero power once the target
temperature was reached. This control scheme was de-
signed to reach the target temperature in the shortest
time, while avoiding damaging temperatures at the foci.
Unlike the diverging beam approach, which avoids hot
spots but lacks a conformal treatment area, the electron-
ically steered focused beam used here carries the risk of
overheating the tissue at and around the individual foci.
Rapid steering between foci and accurate monitoring is
therefore required to avoid reaching ablative tempera-
tures. In our experiments, we have set the maximum
sonication power low enough to limit the temperature
increase while the beam is focused at each cell of the
grid during image acquisition (~ 2 s until a new
temperature image is acquired). This could be further
improved by continuously switching between several of
foci (e.g. the three coldest cells), effectively spreading
out the heat without the need for a faster image acquisi-
tion time. Diffused ultrasound focal fields [36] could also
be implemented to the same effect. To avoid overheating
at the foci during acquisition of monitoring images and
in case of system malfunction, we have also imple-
mented a safety feature that sets the power output to
zero if no thermometry images in the control plane are
received within 3 s.
Near field heating remains a problem due to the small
active area and aperture of the endorectal transducer
(23 × 40 mm), and the overlap or intersection of beam
coronal slice
6:06 s 8:18 s 10:29 s
0
5
10
15°
- 0:28 s
probe
axial slice
1:43 s 3:55 s
Fig. 6 Coronal MR thermometry images used for beam control (upper row) from different time points during the experiment, and axial images
(lower row) used for near-field monitoring, acquired during experiment 4. The labels show the time from the heating start (focused ultrasound
power on). Flow artifacts within the water surrounding the phantom and in the balloon surrounding the transducer did not affect image quality
within the phantom
Ozhinsky et al. Journal of Therapeutic Ultrasound  (2018) 6:7 Page 7 of 10
paths for the different foci. Our results showed excessive
near-field heating for the 60 mm focal depth, which re-
duced to acceptable levels for the 35 mm focal depth.
Therefore, with this transducer it may be difficult to
achieve therapeutic temperatures localized at deep levels
(greater than 40 mm) without incurring excessive temper-
atures in the near field. However, this depth limitation
would be sufficient for HT treatments within prostate for
a majority of patients. Based upon review of 800 prostate
MRI exams performed at our institution, the mean
anterior-posterior length of the gland was 3.4 cm, with the
95%ile = 4.7 cm, max = 7.2 cm (Susan Noworolski, Ph.D.,
personal communication). Pre-cooling the tissue with cir-
culating water before and throughout the treatment helps
to protect the rectum and tissue close to the transducer
from over-heating and to move the effective treatment en-
velope away from the transducer, as was demonstrated in
experiment 4. In vivo, blood perfusion is likely to lower
the temperature elevation in the near field, as compared
to the phantom experiments, but may also require more
energy deposition to reach the target temperature. If pre-
cooling is used, the MR thermometry should cover the
cooling period in order to accurately monitor the actual
temperature change. Further development of this ap-
proach should include 3D temperature sampling, which
would take into account temperature throughout the
whole treated volume while controlling the ultrasound
beam power and focusing.
As is the case with all phase difference based PRF
thermometry methods, temperature errors due to mo-
tion, phase drift or susceptibility changes can occur.
Due to the long temperature imaging duration for
hyperthermia applications, phase drift could be a prob-
lem on some scanners. Several prospective or retro-
spective drift correction techniques, such as center
frequency adjustment and post-acquisition correction
as evaluated for hyperthermia by Bing et al. [37] can be
applied to ameliorate the problem. In our study, correc-
tion for phase drift over less than 20-min duration was
not necessary.
In MR thermometry, there is an inherent trade-off be-
tween temporal resolution and temperature uncertainty.
MRgHT in general does not require fast imaging due to
the diffuse heating and slow temperature rise [38]. On the
other hand, the quick temperature rise in ablative proce-
dures requires high temporal resolution (~ 1–3 s in
non-moving organs). Similarly, accelerated MR thermom-
etry was crucial for multi-focal rapid beam steering with
feedback control, implemented in this project. Our accel-
eration parameters achieved 2 s update time using shared
k-space with keyhole k-space sampling scheme. This re-
sulted in a temperature uncertainty of 0.5 °C in our phan-
tom experiments, which would be adequate to monitor
hyperthermia within the prostate. In vivo, temperature
uncertainty might be slightly higher, but could be im-
proved by using multi-channel MR imaging coils.
To avoid image artifacts in thermometry frames follow-
ing switching image orientations, dummy excitations with
data acquisition disabled could be performed until
magnetization reaches the steady state. Other acceleration
techniques, such as echo-planar and non-Cartesian read-
outs, parallel imaging, and compressed sensing could
allow for higher acceleration factors. Shared k-space with
keyhole scheme was chosen since it was found to be ro-
bust to susceptibility artifacts near the focused ultrasound
transducer. It did not require the use of multi-channel
coils and allowed for minimal reconstruction delay. It is
likely that a higher frame rate and/or more imaging slices
could be achieved by further optimizing the keyhole width
and the number of interleaves. The k-space sampling
order could also be altered to acquire center lines last, en-
suring more accurate temperature measurement at the
time of reconstruction [39].
The main limitation of the current study is that phan-
tom experiments do not precisely model the thermal
and acoustic properties of in vivo tissue, such as tissue
heterogeneity and the heat sink effect in tissue due to
blood perfusion. Additional studies are necessary to as-
sess the heating performance of this integrated system in
in-vivo preclinical models.
Conclusions
We have implemented a real-time MR thermometry-
guided system for hyperthermia delivery within user-de-
fined regions with the ExAblate prostate array and
evaluated it in phantom experiments for different shapes
and focal depths. Our results showed that uniform heating
can be achieved and maintained at hyperthermic tempera-
tures in the focal region. Near-field heating can be exces-
sive for large focal depth but appears to be acceptable for
geometries of normal sized prostates when precooling is
applied. The shared k-space with keyhole acceleration
pulse sequence acquired images with a 2 s update rate and
provided a temperature accuracy of 0.5 °C, which was ad-
equate for power and shape control during the HT experi-
ments. Our results demonstrate the feasibility of using a
commercially available endorectal FUS transducer to per-
form spatially-conformal hyperthermia therapy and could
lead to a new set of exciting applications for these devices.
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